The PSMB5 (Proteasome Subunit Beta 5) gene encodes the beta5 subunit of the 20S proteasome core particle, the principal proteolytic enzyme responsible for degrading ubiquitinated proteins in eukaryotic cells. Located at chromosomal position 14q11.2, PSMB5 is one of seven beta subunits that form the inner catalytic rings of the proteasome barrel. This gene encodes the chymotrypsin-like proteolytic activity, which is the primary activity responsible for protein degradation and is the target of the anti-cancer drug bortezomib.
| Gene Symbol | PSMB5 |
| Full Name | Proteasome Subunit Beta 5 |
| Chromosomal Location | 14q11.2 |
| NCBI Gene ID | 5693 |
| OMIM | 177046 |
| Ensembl ID | ENSG00000100814 |
| UniProt | P28074 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Cancer |
PSMB5 encodes the beta5 subunit of the 20S proteasome, also known as the LMP7 subunit in the immunoproteasome context. PSMB5 carries the chymotrypsin-like proteolytic activity, which cleaves after hydrophobic amino acid residues and is the rate-limiting step in protein degradation. This makes PSMB5 the most catalytically important subunit and the primary target of proteasome inhibitor drugs[1].
The 20S proteasome is a 28-subunit protease organized as a four-ring stack. The two inner beta rings contain seven subunits each, with PSMB5, PSMB1, and PSMB2 providing the three catalytic activities: chymotrypsin-like (PSMB5), caspase-like (PSMB1), and trypsin-like (PSMB2)[2].
PSMB5 assembles with six other beta subunits to form the proteolytic beta rings:
PSMB5 cleaves peptide bonds after hydrophobic residues (Phe, Leu, Trp, Tyr):
In neurons, PSMB5-mediated proteasome activity is critical for:
PSMB5 activity is significantly reduced in AD brain:
alpha-Synuclein degradation is dependent on proteasome activity:
PSMB5 is the primary target of proteasome inhibitor drugs:
PSMB5 is ubiquitously expressed with high levels in metabolically active cells:
PSMB5 is a validated drug target:
The study of Psmb5 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Groll et al. [Structure of the 20S Proteasome (2000)](https://doi.org/10.1016/S0092-8674(00). 2000. ↩︎
Ciechanover, The Ubiquitin-Proteasome Pathway (2015). 2015. ↩︎
Kisselev et al. [Proteasome Catalytic Sites (1999)](https://doi.org/10.1016/S0092-8674(00). 1999. ↩︎
Tai & Schuman, Proteasome in Synaptic Plasticity (2010). 2010. ↩︎
Gregori et al. Proteasome Dysfunction in AD (1995). 1995. ↩︎
McNaught et al. Proteasome Impairment in PD (2002). 2002. ↩︎